High levels of sFas and PBMC apoptosis before and after excision of malignant melanoma--case report.
In our study we investigated the level of apoptosis in PBMCs and the serological level of sFas (CD95/APO-1) in 22 patients with malignant melanoma (12 patients with unique cutaneous primary tumour and 10 patients with unique brain metastasis). The first determination was performed before tumour excision and the second at 6-7 months after excision. Results in patients with primary tumour in the first determination: 6 patients with over normal values in PBMCs apoptosis and 5 patients with increased values of sFas. In the second determination: apoptosis was increased in 5 patients and sFas level was increased in 4 cases. In patients with metastases in the first determination apoptosis of PBMC was increased in 7 cases and sFas in 5 cases. In the second determination apoptosis was increased in 4 cases and sFas was increased in 4 cases. Our results show that half of the investigated patients presented elevated values of PBMCs apoptosis and Fas receptor both before and 6-7 months after tumour excision. Apoptosis values for PBMCs and sFas values were with 1/4 higher than normals. There was no difference in clinical evolution of the patients with normal or increased values for studied parameters. Clinical evolution was performed for 1 year. The presence of increased values for PBMCs and sFas after tumour excision, primary or metastasis is surprising and hard to explain. It is possible that tumoral evolution induces a disregulation at PBMCs level or other cells level that persists unexpectedly, after tumour excision or apoptotic processes, in a certain level to be independent and anterior to tumour development.
Alecu
M
M
Dermatology Research Centre, Scarlat Loghin Dermatology Hospital, Calea Serban Vodă 216, 75202, Bucharest, Romania.
Coman
Gabriela
G
Dănăilă
L
L
D017209:Apoptosis; D001932:Brain Neoplasms / Q000556:secondary; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000502:physiology*; D008545:Melanoma / Q000556:secondary / Q000601:surgery*; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery*; D012995:Solubility; D019014:fas Receptor / Q000097:blood*
D019014:fas Receptor